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Why was the cohort set up?
Hepatitis C is a blood-borne virus that causes scarring and
inflammation of the liver.1 The virus is also associated
with extrahepatic disease, including non Hodgkins lymph-
oma,2 renal disorders3 and, probably, cardiovascular dis-
ease.4 Chronic hepatitis C virus (HCV) infection-referring
to persistent carriage of the virus is a global problem af-
fecting in excess of 140 million individuals5 and causing
half a million deaths every year from liver disease.6
HCV Research UK is a consortium of leading stake-
holders in the UK, including all the major adult and paedi-
atric liver centres. The remit of HCV Research UK is to
address critical gaps in our understanding of this virus.
These gaps exist particularly in relation to: (i) the clinical
course of HCV-related disease; (ii) the optimal clinical
management of the virus (including the effectiveness and
long-term impact of antiviral therapies); and (iii) the viral
and host genetic factors influencing prognosis.
The HCV Research UK clinical database and biobank
was set up in 2012 to advance our knowledge in these
areas. It includes in excess of 10 000 patients from across
the UK, who have attended a specialist HCV clinic for
care/management of their HCV infection. Extensive
epidemiological and clinical data have been collected for
each participant, both at baseline and longitudinally there-
after, but the unique strength of this cohort is that each
participant has further submitted a blood specimen for se-
cure storage in a biorepository (‘biobank’). These biolo-
gical samples can be used for viral and host genotyping as
well as other appropriate research analyses. It is envisaged
that integrating biological, epidemiological and clinical
data in this way will encourage a more multidisciplinary
approach to HCV research.
The clinical database is managed at the University of
Nottingham, and the biobank is sited at the Centre for
Virus Research (CVR) along with a satellite biobank at the
University of Birmingham. In this profile report, we pro-
vide a broad overview of this cohort, including a detailed
description of the participants, a summary of the data col-
lected and an outline of its successes so far.
Who is in the cohort?
In total, 10 184 patients with past or current chronic infec-
tion were enrolled into the cohort through attendance at one
of 56 specialist UK HCV clinics between March 2012 and
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July 2015. Figure 1 illustrates the geographical distribution
of these specialist clinics and the overall contribution of each
UK region to the cohort. Almost all of the highly populated
parts of the UK are represented in the cohort, with most par-
ticipants recruited from Yorkshire, London, the West
Midlands and Glasgow. Exclusion criteria for recruitment
included an inability to obtain informed consent or being de-
tained in prison at the time of clinic appointment. Table 1
shows that the vast majority (82.6%) of participants re-
cruited were existing patients of the specialist HCV clinic
and had been in attendance for a median of 3.7 years [inter-
quartile range (IQR] 1.3–8.1). Otherwise, 15.2% of the final
cohort were recruited as new referrals to the HCV clinic, and
thus their date of cohort enrolment coincides with their first
attendance date at the specialist centre. The remaining 2.3%
of the cohort were patients who had previously attended a
specialist HCV clinic but had been discharged following
clearance of their infection through antiviral treatment
(known as a sustained virological response or SVR). These
patients who had achieved an SVR were invited back to par-
ticipate in this cohort and would not have attended the clinic
otherwise.
Table 2 describes some of the key characteristics of the
cohort. The mean age at baseline is 48.5 years, and al-
though most (58%) participants were aged between
45 and 64 years, the cohort also includes a subgroup of
85 children (age<16 years). Overall, participants are typ-
ically male (70.9%), of White ethnicity (83.4%) and
acquired their infection through injecting drug use
(53.9%). The average duration of infection at enrolment is
in excess of 20 years (23.4 years). At enrolment, the major-
ity had current chronic infection, although an important
subset (13.4%) had past chronic infection which they had
previously cleared through treatment (i.e. through attain-
ing an ‘SVR’). In terms of the clinical consequences of
chronic infection, almost a quarter of the cohort have been
diagnosed with liver cirrhosis, in either compensated
(18.2%) or decompensated form (5.2%), and 2% of par-
ticipants had liver cancer. Of the specialist HCV clinics
participating in HCV Research UK (see Figure 1), around
50% of their total HCV clinic population were recruited
into our final cohort (based on available data from 29 clin-
ics). To assess how representative this cohort is of all pa-
tients attending specialist care, we compared the broad
demographics of our final cohort with those of all patients
attending clinical services in Scotland (the only region in
the UK where a national clinical database of HCV at-
tendees exists). Table 3 shows that HCV Research UK par-
ticipants recruited from Scottish centres are broadly
comparable to all Scottish attendees in terms of age, gen-
der, and ethnicity. The only notable difference was that for
the HCV Research UK cohort, patients were less likely to
Figure 1. Breakdown of HCV Research UK cohort sites (N¼ 56) and participants (N¼ 10 184) by geographic region.
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be assigned an unknown route of infection (10.4% in
Scottish HCV Research UK participants versus 25.2% for
all Scottish attendees). This may reflect a more extensive
probing for risk factor data in HCV Research UK than that
carried out routinely in the Scottish national database.
Within the HCV Research UK cohort described above,
are two subgroups that have been subject to more detailed
investigation and scrutiny. The first subgroup comprises
individuals who took part in the NHS England Expanded
Access Programme (EAP) that was launched in June 2014
(N¼ 806) [7]. The purpose of this programme was to pro-
vide patients at greatest need (i.e. mainly those with
advanced liver disease) with early access to the new but
highly costly all-oral antiviral regimens. The second sub-
group comprises patients who participated in the STOP-
HCV study (N¼4000) [www.stop-hcv.ox.ac.uk]. STOP-
HCV is a £5.2 million MRC-sponsored study that aims to
use epidemiological, clinical and genetic patient informa-
tion to establish the most effective and cost-effective treat-
ments for patients with HCV. Within this STOP-HCV
subgroup is a further notable subset of patients who are
taking part in the STOP-HCV cirrhosis sub-study
(N¼ 1200). This cirrhosis sub-study is a 5-year prospective
investigation into the determinants of liver disease progres-
sion in patients with compensated cirrhosis.
Further to the 10 184 individuals with past/current
chronic infection, HCV Research UK also recruited
275individuals with ‘spontaneously resolved’ infection.
Spontaneous resolution refers to natural clearance of HCV
without treatment, and occurs in a quarter of all persons
infected (usually within 6 months of the initial infection
event).8 Because the number of spontaneous resolvers
recruited was small and because spontaneous resolvers
are not ordinarily referred to specialist clinics for care/
management of HCV infection, these participants were
treated as distinct and not included in the data tables of
this profile.
Finally, there is ongoing recruitment of 1200 patients
receiving therapy containing second-generation (i.e. not
telaprevir or boceprevir) direct-acting antiviral agents in rou-
tine clinical practice [direct-acting antivirals (DAA) study].
What has been measured and collected?
HCV Research UK collects baseline clinical and epidemiolo-
gical data through a standardized questionnaire that is com-
pleted for each participant at enrolment. Follow-up data are
collected mainly through assessment of patient medical notes.
Table 4a provides a broad overview of the clinical and epi-
demiological information collected on each participant. In
brief, the data collected relate to: (i) demographic factors;
(ii) acquisition of HCV; (iii) health risk behaviours; (iv) phys-
ical characteristics of participant; (v) hepatitis C virology; (vi)
comorbid health conditions; (vii) co-medications; (viii) liver
disease status; (ix) HCV antiviral treatment episodes; (x) rou-
tine laboratory tests; and (xi) vital status. All data are entered
directly at the recruitment site into the database by trained
clinical staff. The database itself is hosted by an IT company
(Illuminaries Ltd) on a server behind the NHS firewall. At the
time of enrolment, each patient is assigned a unique study
number that is used to link the above clinical/epidemiological
data with biological samples. These biological samples take
the form of blood specimens that are drawn at enrolment,
and sent by overnight courier at ambient temperature to the
central biorepository at the CVR. On arrival, samples (serum
and plasma) are processed, aliquoted and placed in long-term
storage at -80C. The buffy coat layer from EDTA-treated
blood is also collected and stored for preparation of DNA.
Full-length next-generation sequencing of viral RNA is being
carried out on  2000 individuals. This includes the 806 par-
ticipants with advanced liver cirrhosis, who were treated with
all-oral DAAs in the NHS England EAP,7 and also patients in
the STOP-HCV cirrhosis study. Host genotyping has been
performed on 4000 participants and has focused on pa-
tients with genotype 3 infection and/or cirrhosis (see Table
4b). Host genotyping was carried out using the Affymetrix
UK biobank microarray, which generates data on  800000
single nucleotide polymorphisms, including polymorphisms
in the interleukin 28b gene (on chromosome 19) that have
previously been shown to influence hepatitis C treatment
response9 and liver disease progression.10
How often have they been followed up?
Data on health risk behaviours, physical characteristics,
HCV virology, comorbidities, co-medications, liver disease
status, antiviral treatment episodes and mortality status
are collected at least biennially for all participants in the
cohort (see Table 4a). Enhanced follow-up data for key
Table 1. Break down of HCV Research UK cohort (N¼10 184)
according to recruitment approach and time between first ap-
pointment at specialist clinic and enrolment
Recruitment
approach
N (%)* Years from first
clinic attendance
to enrolment,
median (IQR)
New attender 1476 (15.2) 0 (0.0–0.1)
Existing attenders 8039 (82.6) 3.7 (1.3–8.1)
Discharged sustained
viral responder
219 (2.3) 8.1 (3.2–12.6)
Unknown 450 (–) 1.7 (1.7–4.3)
*Percentages exclude individuals with unknown recruitment approach.
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Table 2. Description of the final cohort at the time of enrolment (N¼ 10 184)
Characteristic N (%)
Demographic factors Age in years <16 85 (0.8)
16–44 3423 (33.7)
45–64 5934 (58.4)
65þ 718 (7.1)
Missing 24 (0.2)
mean age (SD) 48.5 (11.7)
Gender Female 2950 (29.0)
Male 7190 (70.6)
Other/missing 44 (0.4)
Ethnic group White 8496 (83.4)
Asian/Asian British 1004 (9.9)
Black/African/Caribbean/Black British 223 (2.2)
Mixed/multiple ethnic groups 103 (1.0)
Other 256 (2.5)
Unknown 102 (1.0)
Country of birth UK 7391 (72.6)
non-UK 2591 (25.4)
NK/missing 202 (2.0)
Hepatitis C
infection factors
Route of infection/
risk group
Injecting drug use 5290 (51.9)
Blood transfusion/blood products 1158 (11.8)
Born abroad 1006 (9.9)
Sexual transmission 335 (3.3)
Perinatal transmission 98 (1.0)
Other 1074 (10.6)
No known risk factor 657 (6.5)
Missing 566 (5.6)
Estimated duration
of infection*
<20 yrs 2840 (27.9)
20yrsþ 4214 (41.4)
unknown 3130 (30.7)
Median duration, years (IQR) 24 (13–32)
Genotype 1 4770 (46.8)
2 446 (4.4)
3 3646 (35.8)
4,5,6 338 (3.3)
Mixed genotype 14 (0.1)
Missing/NK 970 (9.5)
Clinical factors Antiviral treatment
history
Never treated 4002 (39.3)
Currently being treated 1511 (14.8)
Previously treated and cleared infection (i.e. SVR) 1366 (13.4)
Previously failed treatment (i.e. non-SVR) 2947 (28.9)
Missing/NK 358 (3.5)
Liver-related
consequences of
hepatitis C infection
Diagnosed with liver cirrhosis No 7803 (76.6)
Yes - compensated cirrhosis 1851 (18.2)
Yes - decompensated cirrhosis 530 (5.2)
Diagnosed with liver cancer No 9981 (98.0)
Yes 203 (2.0)
Prior liver transplantation No 9674 (95.0)
Yes 495 (4.9)
Unknown 15 (0.2)
All patients 10184
*For individuals who acquired their infection via injecting drug use, the duration of infection was estimated by subtracting the year of enrolment into HCV
Research UK from the year of first injection. We then subtracted a further 3 years from this, which relates to the average time from commencing injecting drug use
to acquiring HCV infection (Hagan et al, Epidemiology. 2004;15(5):543–9).
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strategic subgroups of the cohort are also being captured
(see Table 4b). This includes the collection of routine la-
boratory data for all individuals who took part in the NHS
England EAP, and for individuals in the STOP-HCV cir-
rhosis sub-study. Prospective follow-up data on health care
utilization encompassing information on HCV-related
clinic visits, treatment of adverse effects from antivirals,
and general hospital admissions are also being collected for
those patients in the EAP. Such data on health care utiliza-
tion are intended to inform estimates of treatment cost-
effectiveness which is currently a critical topic within HCV
research, given the high cost of new medicines.11 Finally,
in time, prospective data collection for the bulk of the co-
hort on hospital admissions and cancer registries is planned
through record linkage to UK nationwide health registries.
What has it found? Key findings and
publications
Although the merits of clearing HCV through antiviral
treatment are well studied for patients with compensated
(i.e. asymptomatic) liver disease, little is known about the
benefits of treatment once advanced symptomatic disease
has set in. This cohort has duly contributed one of the first
studies to address this gap in the evidence base.12 The
study examined the impact of antiviral treatment on a pa-
tient’s Model for End-Stage Liver Disease (MELD) score,
which is a surrogate measure of liver function and ranges
from a value of 6 (representing the lowest illness severity)
up to a value of 40 (representing the highest illness sever-
ity). Among 467 patients with advanced liver disease, who
received a 12-week course of antiviral treatment, the mean
post-treatment MELD score was modestly lower than the
mean pre-treatment MELD score (mean improvement of -
0.85). In contrast, among 261 untreated patients followed
up for a comparable time frame, the MELD score deterio-
rated (mean change of þ0.75). This provides some initial
evidence that antiviral treatment may be of value to pa-
tients with advanced disease albeit, going forward, it will
be important to confirm this putative benefit against hard
clinical endpoints such as all-cause mortality. Otherwise,
there is a rich pipeline of research projects that are
Table 3. Characteristics of patients enrolled into the HCV Research UK cohort compared to all patients attending hepatitis
C specialist services in Scotland
Characteristic HCV Research UK Scottish National HCV
clinical database
All centres
(N¼10,184)
Scottish Centres
(N¼1785)
All HCV patients
attending Scottish specialist
services, April 2012–April
2015, (N¼9787)
N(%) N(%) N(%)
Gender Female 2950 (29.0) 496 (27.8) 2894 (29.6)
Male/other/missing* 7234 (71.0) 1289 (72.2) 6893 (70.4)
Age in years <16 85 (0.8) 0 (0.0) 18 (0.2)
16–44 3423 (33.7) 840 (47.1) 5671 (57.9)
45–64 5934 (58.4) 876 (49.1) 3815 (39.0)
65þ 718 (7.1) 63 (3.5) 283 (2.9)
Missing 24 (0.2) 6 (0.3) 0 (0.0)
mean age (SD) 48.5 (11.7) 45.2 (10.2) 43.4 (14.3)
Ethnic group White 8496 (83.4) 1697 (95.1) 9327 (95.3)
Asian/Asian British 1004 (9.9) 60 (3.4) 294 (3.0)
Black/African/Caribbean/Black British 223 (2.2) 7 (0.4) 29 (0.3)
Any other 359 (3.5) 17 (1.0) 52 (0.5)
unknown 102 (1.0) 4 (0.2) 85 (0.9)
Route of infection/risk group Injecting drug use 5290 (51.9) 1203 (67.4) 6031 (61.6)
Blood transfusion/blood products 1158 (11.4) 168 (9.4) 530 (5.4)
Sexual transmission 335 (3.3) 60 (3.4) 215 (2.2)
Other** 2178 (21.4) 168 (9.4) 548 (5.6)
unknown/ no known risk factor 1223 (12.0) 186 (10.4) 2463 (25.2)
*Males collapsed with other/missing category to minimise risk of disclosure and to help maintain confidentiality.
**The “born abroad” risk group for HCV Research UK participants has been collapsed into the “other” category, because no equivalent risk group to “born
abroad” exists in the Scottish clinical database. “Perinatal transmission group has also been collapsed into “other” to minimise the risk of disclosure and to help
maintain confidentiality.
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currently in progress. For example, this cohort underpins
the aforementioned MRC-funded STOP-HCV study,
which aims to inform how a ‘stratified medicine’ approach
can be applied to the treatment of hepatitis C. Further, the
Tissue and Data Access Committee (TDAC) of HCV
Research UK have thus far approved more than 65 applica-
tions from academia and industry for access to data and
samples. These applications cover a broad range of topics
and scientific disciplines, including lipidomics, metabolo-
mics and proteomics, in addition to proposals for more
traditional epidemiological studies such as investigating
the association between alcohol and disease progression.
From our own initial review of the data, one particular
topic that stands out as being worthy of in-depth research
is the singular behaviour/comorbidity profile of this co-
hort. Table 5 shows that almost 40% have a history of
Table 4b. Overview of enhanced data collection for strategic subgroups of the HCV Research UK cohort
Subgroup N (% of full cohort) Additional data collected
Participants taking part in the NHS
England early access programme
806 (7.9%) Data on : 1) routine laboratory results collected annually; 2) prospective
health resource utilisation data*; 3) viral sequencing on baseline, during-
therapy and post-therapy samples; 4) host genotyping for 800,000 single
nucleotide polymorphisms
Genotype 3 infected participants
taking part in STOP-HCV
2000 (19.6%) Data on : 1)host genotyping for 800,000 single nucleotide polymorphisms
Participants in the STOP-HCV
cirrhosis sub-study
1200 (11.8%) Data on : 1) routine laboratory results collected annually; 2) viral sequencing
on baseline samples; and 3) host genotyping for 800,000 single nucleo-
tide polymorphisms
*Refers to data on all HCV-related clinic visits; treatment of adverse effects from antivirals; and general hospital admissions.
Table 4a. HCV Research UK cohort: summary of epidemiological and clinical data collected for all participants
Category Major variables captured Time point
Enrolment Follow-up
(at least bienially
following enrolment)
1: Socio-demographic factors gender; age; country of birth; ethnicity; recruitment approach;
first clinic attendance date
Y N/A
2: HCV acquisition route of infection; estimated year of infection, date of HCV
diagnosis
Y N/A
3: Health risk behaviours data on: alcohol use; drug use; tobacco smoking; and cannabis
smoking
Y Y
4: Physical characteristics Height, weight, BMI Y Y
5: HCV virology HCV genotype; HCV genotype subtype; viral RNA positivity
status; quantitative viral load
Y Y
6: Comorbid health conditions presence of: renal failure; diabetes; cancer; depression; HIV co-
infection; coagulation bleeding disorder; cryoglobulinaemia
Y Y
7: Co-medications taken use of: anti-diabetics, anti-depressants, anti-retrovirals, hyp-
notics, immunosupressive drugs; opiate substitution therapy;
steroids; statins
Y Y
8: Liver disease status data on: liver transplantation; liver biopsies performed; diag-
nosis of cirrhosis; portal hypertension; diagnosis of decom-
pensated cirrhosis; diagnosis of liver cancer; fibroscan
scores.
Y Y
9: Hepatitis C antiviral treatment data on HCV antiviral treatment episodes including: outcome
(i.e. viral clearance), treatment regimen;duration of treat-
ment and side effects.
Y Y
10: Routine laboratory data liver function tests; full blood counts; lipid profile tests; blood
sugar tests; and renal function tests
Y N
11. Vital status data on date and cause of death N/A Y
Y¼ Yes; N¼No; N/A ¼ not applicable.
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heavy alcohol use, 6.6% have recently injected drugs, 54%
are current smokers and 16% have previously attempted
suicide; all these statistics are vastly out of step with the
crude prevalence reported for the UK general population.
Epidemiological studies to disentangle the impact on
health of chronic infection itself versus these concomitant
conditions would be of real value, as would the investiga-
tion of appropriate interventions to redress high levels of
heavy alcohol use, drug use and mental health issues.
What are the main strengths and
weaknesses?
This cohort has several notable strengths. Foremost, this is
one of the largest HCV clinical database and biobank re-
sources to have been established anywhere in the world.
This resource will therefore open the door to new types of
research study for instance, large-scale genome-wide asso-
ciation studies to identify host polymorphisms that influ-
ence liver fibrosis progression and development of
hepatocellular carcinoma. Second, we have recruited
across most of the geographical area of the UK, creating a
network of 56 sites that includes the largest tertiary clinical
centres that manage the care of HCV-infected individuals.
As a consequence, it will be possible to map the viral
strains and genotypes which currently circulate in the UK,
aiding the identification of transmission networks and
sub-groups with particular characteristics (e.g. those with
cirrhosis). Such information could potentially inform pre-
vention strategies and enable identification of any emerg-
ing novel resistant strains that arise as a consequence of
large-scale use of all-oral, interferon (IFN)-free DAA thera-
peutic regimens. Finally, the cohort is sufficiently large to
allow sub-studies on special-interest patient groups (e.g.
paediatric patients, those with cirrhosis for disease progres-
sion, re-treatment in patients who previously did not re-
spond to therapy and comparison of treatment response to
new therapies across genotypes).
The following limitations should be highlighted. First, of
all patients in attendance at the 56 HCV Research UK clinics
Table 5. Prevalence of selected health conditions/behaviours among participants of HCV Research UK at the time of enrolment
Health condition/behaviour Prevalence among HCV
Research UK participants,
by gender
Crude prevalence in
UK general population
Data source for crude
population prevalence
Recent injecting drug use* Male: 7.8% <1% UK report to European monitoring
centre for drugs and drug addition,
201414
Female: 3.9%
Past injecting drug use Male: 62.4% 1%
Female: 46.6%
Daily/occasional cannabis use Male: 27.7% 7%
Female: 15.8%
Current tobacco smoker Male: 58.0% 19% Health Survey England, 201415
Female: 45.3%
Obesity (BMI30) Male: 20.3% 26%
Female: 24.9%
Underweight (BMI <18.5) Male: 2.6% 2%
Female: 3.5%
Diagnosed with diabetes Male: 11.2% 6%
Female: 9.2%
Previous suicide attempt Male: 15.1% 6%
Female 20.2%
History of sustained heavy alcohol use† Male: 43.2% 2–12%†
Female: 23.6%
Current excess alcohol use‡ Male: 8.7% 18%
Female: 7.7%
Previous hospital admission for depression Male: 9.1% 1% Innes et al16
Female: 12.4%
HIV infected Male: 6.0% <1% Public Health England, 201417
Female: 2.9%
*Recent defined as within the past six months.
†Past sustained heavy alcohol use defined as drinking >50 units a week for at least 6 months. No directly comparable UK population statistic exists for this. As
a lower bound, we have indicated 2% which refers to the prevalence of current alcohol consumption >50 units week taken from Health Survey England. As the
upper bound we have indicated 12% which refers to the lower bound estimate added to the proportion of ex-drinkers in the UK population.
‡Current excess alcohol use refers to drinking >21 units in the last 7 days for males, and >14 units/wk for females.
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(see Figure 1), only an estimated 50% were enrolled into the
cohort. Given this moderate response rate, it is possible that
participants differ from non-participants in epidemiologically
and clinically important ways. Although the broad demo-
graphic comparability between the Scottish contingent of
HCV Research UK and all patients attending an HCV clinic
in Scotland (see Table 3) is reassuring it does not necessarily
disprove the existence of selection bias. Furthermore, the co-
hort is unlikely to be representative of the total UK population
that are living with HCV infection principally because most
infected persons are not currently in contact with specialist
HCV clinics, and indeed many have not even been diag-
nosed.13 These caveats should be borne in mind when inter-
preting data from this cohort. Second, almost all patients in
the cohort had established or previous chronic infection at en-
rolment, and so there are no samples in the biorepository that
span the acute phase of hepatitis C infection. Finally, for longi-
tudinal studies, our collection of serial biological samples is
somewhat limited. However, the 1200 STOP-HCV cirrhosis
study patients will be sampled annually for 5 years, and the
806 patients included in the NHS EAP were serially sampled
at enrolment, during treatment and after treatment.
Can I get hold of the data? Where can I find
out more?
The epidemiological data and biological samples are available
to all researchers in both academia and the biopharmaceutical
industry upon successful application to the HCV Research UK
TDAC. Access requires submission of a formal application to
the HCV Research UK TDAC using an online system avail-
able at [www.hcvresearchuk.org]. TDAC evaluates the merit
of each proposal and also has the authority to grant ethical ap-
proval for any submitted studies. Decisions on submitted ap-
plications take up to 4 weeks, followed by completion of a
Material Transfer Agreement or contract that sets out the
terms for provision of the data and samples. One of the condi-
tions for release of data and samples is that any results gener-
ated would be returned for inclusion in the HCV Research
UK database following their publication. Additional informa-
tion on accessing data and samples can be obtained from ei-
ther of the co-chairs of HCV Research UK: Dr John
McLauchlan [john.mclauchlan@glasgow.ac.uk] or Prof. Will
Irving [will.irving@nottingham.ac.uk], and details regarding
submission of applications are available from the Biobank
Manager, Dr Sarah McDonald [sarah.mcdonald@glasgow.ac.
uk].
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Profile in a nutshell
• HCV Research UK was established to address critical
gaps in our understanding of the hepatitis C virus.
Participants are characterised in terms of epidemio-
logical/clinical factors and have also submitted blood
samples for storage in a bio-repository
• Includes in excess of 10,000 patients from across the
UK who have attended a specialist HCV clinic for
care/management of their HCV infection in 2012-2015
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Physical characteristics; 5. HCV virology; 6. Comorbid
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Access Committee. Applications available at: www.
hcvresearchuk.org
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